Shots:

• The A P-IIb study involves assessing of dapirolizumab pegol vs PBO in adults with moderate-to-severe SLE despite receiving SoC treatment- evaluating safety and efficacy
• The study demonstrated unmet 1EP @24 wks. on the BICLA and showed improvements in majority of clinical endpoints- with safety and tolerability
• Dapirolizumab pegol is an anti-CD40L pegylated Fab jointly developed by UCB &Biogen indicated in SLE. Additionally- Biogen & UCB plans to evaluate the above results

 Ref: Biogen | Image: Biogen